Q3 EPS Estimate for BioLife Solutions Decreased by Analyst

BioLife Solutions, Inc. (NASDAQ:BLFS) – Equities researchers at HC Wainwright reduced their Q3 2026 earnings per share (EPS) estimates for shares of BioLife Solutions in a research note issued on Friday, May 29th. HC Wainwright analyst Y. Chen now forecasts that the medical equipment provider will post earnings per share of $0.01 for the quarter, down from their previous estimate of $0.02. The consensus estimate for BioLife Solutions’ current full-year earnings is $0.09 per share.

Several other brokerages also recently issued reports on BLFS. Weiss Ratings reissued a “sell (d-)” rating on shares of BioLife Solutions in a research note on Monday, April 20th. Zacks Research downgraded BioLife Solutions from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, May 12th. Finally, Wall Street Zen raised BioLife Solutions from a “hold” rating to a “buy” rating in a research note on Saturday, February 28th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $32.00.

BioLife Solutions Stock Performance

Shares of BLFS opened at $24.92 on Monday. The business’s 50 day moving average is $21.25 and its 200 day moving average is $22.84. The company has a market capitalization of $1.22 billion, a PE ratio of -311.46 and a beta of 2.00. BioLife Solutions has a 12-month low of $17.86 and a 12-month high of $29.62.

BioLife Solutions (NASDAQ:BLFS) last issued its earnings results on Thursday, May 7th. The medical equipment provider reported $0.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.03. The company had revenue of $27.50 million for the quarter, compared to the consensus estimate of $25.66 million. BioLife Solutions had a positive return on equity of 1.81% and a negative net margin of 2.80%.

Insider Buying and Selling

In other news, major shareholder Casdin Partners Master Fund, L sold 650,000 shares of BioLife Solutions stock in a transaction that occurred on Thursday, May 21st. The stock was sold at an average price of $23.70, for a total value of $15,405,000.00. Following the completion of the transaction, the insider owned 4,757,165 shares in the company, valued at approximately $112,744,810.50. The trade was a 12.02% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Karen A. Foster sold 96,923 shares of BioLife Solutions stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an average price of $20.15, for a total value of $1,952,998.45. Following the completion of the transaction, the insider owned 113,742 shares of the company’s stock, valued at approximately $2,291,901.30. This trade represents a 46.01% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 1,299,641 shares of company stock valued at $30,134,000. Company insiders own 2.20% of the company’s stock.

Hedge Funds Weigh In On BioLife Solutions

A number of institutional investors and hedge funds have recently modified their holdings of BLFS. T. Rowe Price Investment Management Inc. boosted its holdings in shares of BioLife Solutions by 27.4% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 5,180,824 shares of the medical equipment provider’s stock worth $125,273,000 after purchasing an additional 1,113,972 shares during the period. Bank of America Corp DE boosted its holdings in BioLife Solutions by 73.4% during the 1st quarter. Bank of America Corp DE now owns 904,103 shares of the medical equipment provider’s stock valued at $17,250,000 after acquiring an additional 382,776 shares during the period. Capricorn Fund Managers Ltd purchased a new position in BioLife Solutions during the 4th quarter valued at $9,153,000. Invesco Ltd. boosted its holdings in BioLife Solutions by 9.2% during the 4th quarter. Invesco Ltd. now owns 3,932,191 shares of the medical equipment provider’s stock valued at $95,080,000 after acquiring an additional 332,747 shares during the period. Finally, Granahan Investment Management LLC boosted its holdings in BioLife Solutions by 49.7% during the 1st quarter. Granahan Investment Management LLC now owns 722,057 shares of the medical equipment provider’s stock valued at $13,777,000 after acquiring an additional 239,701 shares during the period. Hedge funds and other institutional investors own 93.24% of the company’s stock.

BioLife Solutions Company Profile

BioLife Solutions (NASDAQ:BLFS) specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife’s product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells.

The company’s flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies.